Fig. 1.

GSCs are more responsive to SHP099 treatment than NPCs. (A) Viability of NPC, GSC 1123, R83, R39, 528, 157, and AC17 cells at 72 h after treatment with SHP099. (B) Comparison of SHP099 IC₅₀ values in A. (C) Effects of SHP099 in limiting dilution glioma sphere-forming assay of GSC R83, R39, and 157 cells. (D) Western blotting (WB) analysis of expression levels of EGFR, p-EGFR, PDGFRα, p-PDGFRα, SHP-2, and p-SHP-2 in NPCs and GSCs. β-actin was used as a loading control. Arrow, EGFR; arrowhead, EGFRvIII. *P < 0.05, **P < 0.01, by one-way ANOVA.